Pfizer first to disclose trial payments
pharmafile | April 1, 2010 | News story | Research and Development, Sales and Marketing |ย ย Pfizer, industry reputation, paymentsย
Pfizer has disclosed in full the payments it has made to US doctors to conduct clinical trials and to promote and educate their peers about its products.
The company is obliged to disclose the information as part of a landmark US government case against it for marketing violations, for which it was fined $2.3 billion in August 2009.
The publication of the figures represents a high water mark for disclosure in the pharma industry, and seems certain to be followed by Pfizerโs peers, such is the momentum for greater transparency in the sector.
The newly published data shows Pfizer paid $35 million to around 4,500 healthcare professionals over the six-month period of July-December 2009.
Approximately1,500 experienced healthcare professionals were paid an average of $5,000 to provide โinput and advice to ensure the company addresses the real needs of clinicians and patientsโ.
Afurther 2,800 healthcare professionals were paid an average of $3,400 to educate their peers about health conditions and promote Pfizer products.
FredaLewis-Hall, MD, Pfizerโs chief medical officer, said: โCollaboration is essential between healthcare professionals and the pharmaceutical industry to ensure todayโs scientific advances truly improve the lives of patients. Our work with clinicians makes possible both product development and the steady improvement of medical standards and patient care.โย
Lewis-Hall added: โPfizer is committed to ensuring these relationships are transparent to the public and are carefully managed, so that we foster trust and sustain our ability to deliver the breakthroughs patients have come to expect from us.โ
Pfizer are the first to disclose report payments made for conducting phase I โ IV clinical trials in addition to disclosing statements for speaking and consulting.
In July 2009 Lilly published its faculty registry that showed it paid an average of $1,000 to 3,400 healthcare professionals in the first quarter of last year for โtheir servicesโ to Lilly.
In December of last year, GlaxoSmithKline published its total spend on speaking and consulting fees paid to US healthcare professionals that totaled $14.6 million. The new US health reform stipulates that all pharma companies must submit how much they pay doctors for their consultation as well as speaking arrangements, meals and all other perks.
Related Content
NICE recommends Pfizerโs new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21stย May 2025ย โย Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failureย on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …
